Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19

Wei Hu; Xiang Zhang; Yuanchang Liu; Teng Liu; Jiale Wen; Xiaopeng Peng; Xin Xie; Weiming Chen

doi:10.1039/d2ra06841a

. 2022 Dec 6;12(54):34808–34814. doi: 10.1039/d2ra06841a

Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19^†

Wei Hu ¹, Xiang Zhang ¹, Yuanchang Liu ¹, Teng Liu ¹, Jiale Wen ¹, Xiaopeng Peng ^1,², Xin Xie ^1,^2,^✉, Weiming Chen ^1,^2,^✉

PMCID: PMC9724693 PMID: 36540243

Abstract

Herein, the preparation of the key triazone-triazole intermediate of ensitrelvir (S-217622) via sequential cyclization and alkylation reaction is described. Firstly, chloromethyl triazole was synthesized through a one-pot tandem process (condensation and cyclization reaction) from commercially available chloroacetamide in a 72% yield. Then, the key triazone-triazole intermediate was obtained in a second one-pot process by N-alkylation with triazone followed by highly selective N¹-methylation with iodomethane in a 54% yield. In addition, two of the main process impurities were synthesized and identified. This novel alternative two-stage one-pot strategy for synthesizing the key triazone-triazole intermediate opens a new avenue for further research and development of ensitrelvir analogs.

The key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19, was synthesized via two-stage one-pot strategy with high efficiency.

Introduction

COVID-19 is an acute respiratory infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)¹ that spread rapidly since it was first identified in January 2020. As of Nov. 30th, 2022, it had infected over 638 million people and claimed over 6.61 million lives.² Paxlovid, a peptide covalent 3C-like protease inhibitor developed by Pfizer Inc.,³ was the first new oral drug approved by the FDA for the treatment of COVID-19,⁴ reducing the risk of hospitalization or death by as much as 89 percent.^3b However, peptide covalent inhibitors exhibit several disadvantages, such as the intrinsic nature of the reactivity, low membrane permeability and low metabolic stability.⁵ Ensitrelvir (S-217622, 1) developed by Shionogi Co., Ltd, Japan, was the first orally active, noncovalent, nonpeptidic SARS-CoV-2 3C-like protease inhibitor.⁶ This approach solved the shortcomings of peptide covalent inhibitors and had favorable drug metabolism and pharmacokinetic (DMPK) profiles for the oral agents.⁷ Phase IIb clinical trials have demonstrated that ensitrelvir can rapidly reduce viral titers and significantly improve clinical symptoms. As of September 2022, Shionogi announced achievement of the primary endpoint for ensitrelvir fumaric acid (S-217622) in the phase 3 part of the phase 2/3 clinical trial in Asia.⁸

As shown in Scheme 1, triazone-triazole 4 is considered a key intermediate for ensitrelvir synthesis. In the Shionogi's synthetic strategy, it was obtained from N-alkylation with triazone 2 and chloromethyl triazole 3 in a 45% yield. Triazone 2 could be efficiently prepared from 3-(tert-butyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione in an exciting yield of 90.2%.^6b However, efficient synthesis of chloromethyl triazole 3 has, to date, proved challenging, so a novel synthetic strategy for chloromethyl triazole 3 and a further N-alkylation reaction to triazone-triazole 4 is needed.

Chloromethyl triazole 3 was obtained by three strategies (Scheme 2). Starting from toxic chloroacetonitrile, the 1,2,4-triazole ring was constructed in three complicated steps with a 54% yield, while N-methyl-N-formylhydrazine was not commercially available (Scheme 2A).⁹ Three redundant multi-steps (hydroxyl-protection, de-protection, and chlorination) were applied in strategy 2B,¹⁰ while two steps (ester-reduction and chlorination) were necessary for the functional group transformation from an ester to a chloromethyl group in strategy 2C.¹¹ Although these methods provide several pathways to chloromethyl triazole 3, major drawbacks, such as the need for multiple steps and poor atom economy, have limited their application. Therefore, exploring practical and efficient strategies for accessing chloromethyl triazole 3 is desirable.

Herein we report a facile and practical strategy for synthesizing the 1,2,4-triazole derivative from commercially available chloroacetamide and use the material to prepare the key triazone-triazole intermediate of clinical candidate drug ensitrelvir.

Results and discussion

Investigation into the preparation of 1,2,4-triazole derivatives

Considering atom economy and seeking to avoid chlorination of a hydroxyl group, for the initial trials we directly employed starting materials incorporating the chloromethyl group (Scheme 3). To explore a similar cyclization strategy as Scheme 2B, an attempt was made to prepare N-formylacetamide 5 from chloroacetyl chloride and chloroacetamide using formamide and ethyl formate, respectively, but the no N-formylacetamide could be subsequently detected by GC-MS.

Consequently, chloroacetamide was instead condensated with N,N-dimethylformamide dimethyl acetal (DMF-DMA) to give active imine 6, and then cyclized with methylhydrazine sulfate.¹² After easy purification by column chromatography, N¹-methylation target product 3 was isolated in a 7.4% yield accompanied by N²-methylation side-product 3a in an 18.3% yield, which indicated low yield and position selectivity for cyclization. Further research revealed that chloromethyl triazole was stable in neutral, acidic and weak alkaline solution but unstable in stronger alkaline solution, such as aqueous potassium carbonate solution.

The poor selectivity and low yield of cyclization of imine 6 and methylhydrazine demonstrated that this was not a good protocol for the preparation of chloromethyl triazole 3. Therefore, the hydrazine hydrate was replaced to obtain de-methyl triazole 7 in a 49% yield for two steps. Further research indicated that 7 has a weak UV absorption peak at 200–400 nm (c = 1 and 10 mg mL⁻¹ in ethanol) and was unstable in alkaline solution accompanied by complicated impurities.

After de-methyl triazole 7 was successfully obtained, its N¹-methylation to chloromethyl triazole 3 was explored. Because of its instability in alkaline solution, the N¹-methylation product was not observed using methylation reagents MeI and Me₂SO₄ (see ESI†). The neutral methylation reagent Me₃O⁺BF₄⁻ showed a similar failure.¹³ In addition, when Ph₃P and methanol were used for a Mitsunobu reaction, no methylated product 3 was generated.¹⁴

Investigation of N-alkylation and N¹-methylation to triazone-triazole 4

The results of the previous investigation showed that de-methyl triazole 7 was a good choice to use in the following research.

De-methyl triazole 7 could not be methylated in alkaline solution, but it could be N-alkylated with triazone 2 to de-methyl triazone-triazole 8 under the conditions of 1.5 equiv. chloromethyl triazole and potassium carbonate in N,N-dimethylformamide at 60 °C in an isolated yield of 25% (Scheme 4). This may be the result of the different pK_b values of the 1-position nitrogen atom of 7 and the 3-position nitrogen atom of 8. After de-methyl triazone-triazole 8 was obtained, N¹-methylation with iodomethane under potassium carbonate was performed and triazone-triazole 4 was isolated by column purification in an 80% yield. To accurately determine the substituted position of the key triazone-triazole 4, a single crystal obtained in volatile ethyl acetate was subjected to X-ray analysis (CCDC 2212798).

Preliminary optimization

Based on the above synthetic strategy for the key intermediate triazone-triazole 4 from chloroacetamide, a preliminary optimization of the preparation of de-methyl triazole 7 was performed.

To reduce material consumption and concentration temperature, 1.05 equiv. DMF·DMA in ethyl acetate was used for the condensation reaction. Considering its instability under aqueous conditions of amine 6, hydrazine hydrate was replaced by hydrazine acetate for the following cyclization. At the same time, in place of acetic acid, a combination of 3.0 equiv. acetic acid in ethanol gave only a 20% yield in the product. However, when the cyclization was performed in 1,4-dioxane and tetrahydrofuran, the isolated yields rose to 70% and 60%, respectively. By a tandem one-pot process, including condensation and cyclization, de-methyl triazole 7 was obtained as a white solid in a 74% yield (Scheme 5) after column purification, which was more efficient than previously reported methods.^9b,15

Next, because of the instability of de-methyl triazole 7 under basic media, different bases were tried for N-alkylation with 2 as shown in Table 1. When several weak bases, including TEA, DIPEA, and NaHCO₃ were used (entries 1–3), the TLC results were poor. When strong bases such as DBU, CH₃ONa, t-BuOK, and aqueous NaOH were adopted (entries 4–7), a below 10% yield in the product was observed. Based on the better result with K₂CO₃, solvent screening for K₂CO₃ was carried out, which indicated that DMF was more efficient than acetonitrile (entries 8–9).

Trials of N-alkylation of 7 and 2^a.

Entry	Base (equiv.)	Solvent	T (°C)	7 (equiv.)	Yield^b
1	TEA (2.2)	DMF	60	1.5	N. R.^c
2	DIPEA (2.2)	DMF	60	1.5	N. R.
3	NaHCO₃ (2.2)	DMF	60	1.5	Trace
4	DBU (2.2)	DMF	60	1.5	Trace
5	CH₃ONa (1.1)	DMF	60	1.5	<10%
6	t-BuOK (1.1)	DMF	60	1.5	<10%
7	NaOH (1.1)	H₂O	60	1.5	Trace
8	K₂CO₃ (2.2)	DMF	60	1.5	25%
9	K₂CO₃ (2.2)	ACN	60	1.5	<15%
10	K₂CO₃ (2.2)	DMF	−20	1.5	Trace
11	K₂CO₃ (2.2)	DMF	0	1.5	Trace
12	K₂CO₃ (2.2)	DMF	R. T.	1.5	40%^d
13	K₂CO₃ (2.2)	DMF	40	1.5	51%^d
14	K₂CO₃ (2.2)	DMF	40	2.0	60%^d

Open in a new tab

The reaction was performed according to the conditions unless otherwise mentioned. A mixture of triazone 2 (100 mg) and base was added into 2 mL of solvent. After 30–60 min, de-methyl triazole 7 was added into the mixture and stirred for 5 h with hourly monitoring by TLC. If necessary, the crude product was obtained by common workup and purified by column purification.

TLC was used to monitor the reaction unless otherwise mentioned.

Not reacted.

Isolated yield.

Based on the combination of K₂CO₃ and DMF, the reaction temperature was further explored. Comparing the yields at different temperatures, a better-isolated yield (51%) was obtained at 40 °C (entry 13) than at −20 °C, 0 °C, r.t. (entry 10–12), and 60 °C (entry 8), which may be due to low reaction activity at lower temperatures (−20 °C, 0 °C, and R.T. entry 10–12) and poor thermodynamic stability at higher temperatures (entry 8). In addition, when de-methyl triazole 7 was increased from 1.5 equiv. to 2.0 equiv. (entry 14), a large amount of de-methyl triazone-triazole 8 was observed. After column purification, the target product was isolated as a white solid in a 60% yield. No further research into controlling the quantity of de-methyl triazole was performed.

Because of similar basic conditions for N¹-methylation of 8, iodomethane was added directly into the reaction mixture of de-methyl triazone-triazole 8 to obtain triazone-triazole 4. By the one-pot process, the key intermediate was isolated as a base in a 54% isolated yield on a gram scale, which decreased the complexity of the operation and maintained similar results as the two individual steps. However, using triethyl amine as base, poor conversion rate was monitored and no desired product 4 was isolated.

Having identified the reaction conditions of 7 and 4, the workup procedure was further investigated. The hydrochloride salt of 7 was obtained by extracting with ethyl acetate and salt-forming using HCl gas in ethyl acetate. The scale-up up a five-gram scale gave a similar result in a 72% yield as a stable hydrochloride salt. In the further optimization of intermediate 4, when triethyl amine was used to basify 7·HCl before adding into the reaction mixture of 2 and potassium carbonate in N,N-dimethylformamide, only viscous residue was obtained with a large of impurities. Intermediate 4 was obtained in a 54% yield using potassium carbonate as base via extraction with ethyl acetate followed by slurrying in tert-butyl methyl ether. Ultimately, as shown in Scheme 5, the two-stage one-pot strategy was successful in the preparation of the key ensitrelvir intermediate.

Subsequently, an impurity assay was performed, including the two potential impurities N-methyl triazone 9 and N²-methyl impurity 10 in triazone-triazole 4, which were generated from unconsumed 2 and probably from de-methyl triazone-triazole 8 with successive with iodomethane in N-methylation reaction, respectively.

To confirm and control the impurities, impurity 9 was easily obtained by triazone 2 with iodomethane as shown in Scheme 6, which was generated in the reaction mixture and removed easily during the workup procedure. By HPLC monitoring, 23% of impurity 9 in reaction mixture was observed, which was reduced to below 1.0% by slurrying in tert-butyl methyl ether. To investigate the selectivity of N²-methylation on the 1,2,4-triazole group, N²-methylation impurity 10 was prepared from triazone 2 and N²-methyl-triazole 3a, which was observed below 5% in the reaction mixture under potassium carbonate in N,N-dimethylformamide and not detected after purification by HPLC. This indicated a high selectivity of N¹-methylation using iodomethane and potassium carbonate to triazone-triazole 4.

Finally, due to the high energy of the 1,2,4-triazole scaffold, the thermodynamic stability of compounds 7, 3, 2, and 4 containing this triazole core was investigated by differential scanning calorimetry (DSC). The results indicated that all four compounds were stable below 100 °C (see ESI†), and safe under the conditions of the reaction and workup procedure.

Conclusion

Starting from commercially available chloroacetamide, a two-stage one-pot strategy was pursued to prepare the key ensitrelvir intermediate triazone-triazole. Firstly, 3-(chloromethyl)-1H-1,2,4-triazole hydrochloride was isolated as a solid in a 72% yield by a tandem one-pot “condensation and cyclization” process. Then, the key intermediate of ensitrelvir was isolated as a solid in a 54% yield by a one-pot “N-alkylation and N¹-methylation” process. The results show that this strategy is suitable for further research and instructive for future drug discovery.

Experimental section

All commercially available materials and solvents were used directly without further purification unless otherwise noted. Thin-layer chromatography (TLC) was performed on 0.25 mm silica gel F-254 plates. ¹H NMR and ¹³C NMR data were recorded with a Bruker spectrometer (400 MHz) using TMS as internal standard and reported relative to residual solvent signals as follows: chemical shift (δ ppm), multiplicity, coupling constant (Hz), and integration. The multiplicities are denoted as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. The ESI mass spectra were determined on a THERMO LTQ. Single Crystal X-ray diffraction data were collected using a Bruker D8 Quest diffractometer (MoKα, λ = 0.71073 Å). DSC was recorded with Netzsch DSC214. HPLC was performed on Waters e2695 Separation Module.

Preparation of 3-(chloromethyl)-1-methyl-1H-1,2,4-triazole hydrochloride (3) and 5-(chloromethyl)-1-methyl-1H-1,2,4-triazole hydrochloride (3a)

2-Chloroacetamide (1.0 g, 10.69 mmol, 1.0 equiv.) was suspended in DCM (10 mL) and N,N-dimethyformamide dimethyl acetal (1.911 g, 16.04 mmol, 1.5 equiv.) was added. The resulting mixture was stirred under 45 °C for 1.5 hours, then concentrated under reduced pressure. The resulting white solid was dissolved in a mixture of THF (6 mL) and acetic acid (6 mL). Methylhydrazine sulfate (1.85 g, 12.83 mmol, 1.2 equiv.) was added and then was stirred under 50 °C overnight.

The reaction mixture was concentrated under reduced pressure, and then diluted with aqueous Na₂CO₃ (20 mL), extracted with DCM (50 mL × 3). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to afford a yellow oil. The residue was purified by silica gel column chromatography (PE to PE/EA = 4 : 1) to give the free bases of the title compounds.

The free bases were added a solution of 1 M HCl in EA respectively, and then evaporated to dryness to give two products. Via TLC using phosphomolybdic acid or bromocresol green as a chromogenic agent, side-product 3a returned a higher R_f value (R_f = 0.4) than chloromethyl triazole 3 (R_f = 0.3). 3-(chloromethyl)-1-methyl-1H-1,2,4-triazole hydrochloride 3 (132 mg, 0.78 mmol) was obtained as a white solid, yield: 7.4%. ¹H NMR (DMSO-d₆, 400 MHz): δ (ppm) 8.61 (s, 1H), 4.71 (s, 2H), 3.86 (s, 3H). The ¹H NMR data met with the publication.¹⁶¹³C NMR (DMSO-d₆, 100 MHz): δ (ppm) 159.41, 145.94, 38.04, 36.56. HRMS (ESI+) m/z calcd for C₄H₇ClN₃⁺ [M + H]⁺: 132.0323, found 132.0324. 5-(Chloromethyl)-1-methyl-1H-1,2,4-triazole hydrochloride 3a (328 mg, 1.95 mmol) was obtained as a white solid, yield: 18.3%. ¹H NMR (DMSO-d₆, 400 MHz): δ (ppm) 8.01 (s, 1H), 4.99 (s, 2H), 3.89 (s, 3H). The ¹H NMR data met with the publication.¹⁷¹³C NMR (DMSO-d₆, 100 MHz): δ (ppm) 151.38, 150.27, 36.02, 34.41. HRMS (ESI+) m/z calcd for C₄H₇ClN₃⁺ [M + H]⁺: 132.0323, found 132.0324.

Preparation of 6-(ethylthio)-1-(2,4,5-trifluorobenzyl)-1,3,5-triazine-2,4-(1H,3H)-dione (2)^6b

To a solution of 6-(ethylthio)-3 t-butyl-1,3,5-triazine-2,4(1H,3H)-dione (5.0 g, 21.81 mmol, 1.0 equiv.) and 1-(bromomethyl)-2,4,5-trifluorobenzene (5.4 g, 23.99 mmol, 1.1 equiv.) in MeCN (20 mL), K₂CO₃ (3.62 g, 26.17 mmol, 1.2 equiv.) was added. The resulting mixture was stirred at 80 °C for 2 hours and then cooled to room temperature. The cooled mixture was diluted with EA (50 mL). The precipitate was filtered, and the filtrate was concentrated under reduced pressure to afford a yellow oil.

The yellow oil was mixed with TFA (10 mL) and stirred at room temperature overnight. After concentration under reduced pressure, the residue was triturated with MTBE to afford 2 (5.1 g, 16.07 mmol) as a white solid, yield: 74%. ¹H NMR (CDCl₃, 400 MHz): δ (ppm) 8.91 (s, 1H), 7.10–6.93 (m, 2H), 5.15 (s, 2H), 3.22 (q, J = 7.4 Hz, 2H), 1.37 (t, J = 7.4 Hz, 3H). The ¹H NMR data met with the publication.^6b¹³C NMR (DMSO-d₆, 100 MHz): δ (ppm) 170.02, 154.71 (ddd, J = 244.5, 10.1, 2.6 Hz), 152.49, 150.13, 150.04–144.75 (m), 119.56 (ddd, J = 16.0, 6.0, 4.0 Hz), 116.53 (dd, J = 20.7, 5.1 Hz), 106.18 (dd, J = 28.3, 21.4 Hz), 40.70 (d, J = 4.4 Hz), 26.43, 13.77. HRMS (ESI+) m/z calcd for C₁₂H₁₁F₃N₃O₂S⁺ [M + H]⁺: 318.0519, found 318.0516.

Preparation of 3-(chloromethyl)-1H-1,2,4-triazole (7) as a base form

2-Chloroacetamide (20.0 g, 213.88 mmol, 1.0 equiv.) was suspended in EA (200 mL) and N,N-dimethyformamide dimethyl acetal (26.76 g, 224.57 mmol, 1.05 equiv.) was added. The resulting mixture was stirred under 50 °C for 1.5 hours, then removed the solvent under reduced pressure. The resulting white solid was dissolved in a mixture of 1,4-dioxane (120 mL) and acetic acid (38.53 g, 641.64 mmol, 3.0 equiv.). Hydrazine acetate (23.64 g, 256.66 mmol, 1.2 equiv.) was added and then the mixture was stirred under 50 °C overnight. When hydrazine acetate was added, the reaction system immediately turned into a white suspension, which was clarified and turned pink during the heating process. Surprisingly, it proved difficult to monitor the reaction by TLC using common chromogenic methods except for bromocresol green.

The reaction mixture was concentrated under reduced pressure, and then diluted with water (400 mL), extracted with EA (400 mL × 3). The combined organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to obtained a yellow oil. The residue was purified by silica gel column chromatography (PE to PE/EA = 1 : 1) to give 3-(chloromethyl)-1H-1,2,4-triazole 7 (18.60 g, 158.27 mmol) as a white solid, yield: 74%. ¹H NMR (DMSO-d₆, 400 MHz) δ (ppm) 14.05 (br s, 1H), 8.47 (s, 1H), 4.76 (s, 2H). The ¹H NMR data met with the publication.^9b¹³C NMR (DMSO-d₆, 100 MHz) δ (ppm) 158.84, 146.20, 37.93. HRMS (ESI+) m/z calcd for C₃H₅ClN₃⁺ [M + H]⁺: 118.0167, found 118.0181.

Preparation of 3-[(1H-1,2,4-triazol-3-yl)methyl]-6-(ethylthio)-1-(2,4,5- trifluorobenzyl)-1,3,5-triazine-2,4(1H,3H)-dione (8)

To a solution of material 2 (1.0 g, 3.15 mmol, 1.0 equiv.) in DMF (5 mL), K₂CO₃ (958 mg, 6.93 mmol, 2.2 equiv.) was added. The resulting mixture was stirred under 40 °C for 0.5 hour, and then 3-(chloromethyl)-1H-1,2,4-triazole 7 (741 mg, 6.30 mmol, 2.0 equiv.) was added. The mixture was stirred for 5 hours.

The reaction mixture was diluted with water (100 mL), extracted with DCM (300 mL × 3). The combined organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to afford a residue. The residue was purified by silica gel column chromatography (PE to PE/EA = 1 : 2) to give 8 (753 mg, 1.89 mmol) as a white solid, yield: 60%. ¹H NMR (DMSO-d₆, 400 MHz): δ (ppm) 8.26 (s, 1H), 7.73–7.57 (m, 1H), 7.56–7.43 (m, 1H), 5.11 (s, 2H), 5.05 (s, 2H), 4.59 (s, 1H), 3.15 (q, J = 7.4 Hz, 2H), 1.28 (t, J = 7.3 Hz, 3H). ¹³C NMR (100 MHz, DMSO-d₆) δ (ppm) 169.73, 155.89, 155.21 (ddd, J = 245.1, 10.0, 2.5 Hz), 151.81, 150.67, 150.57–145.08 (m), 147.24, 119.61 (dt, J = 16.3, 4.9 Hz), 116.66 (dd, J = 20.7, 5.1 Hz), 106.75 (dd, J = 28.2, 21.6 Hz), 56.09, 49.05, 42.06 (d, J = 4.4 Hz), 26.96, 14.19. HRMS (ESI+) m/z calcd for C₁₅H₁₄F₃N₆O₂S⁺ [M + H]⁺: 339.0846, found 339.0854.

Preparation of 6-(ethylthio)-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-(2,4,5-trifluoro-benzyl)-1,3,5-triazine-2,4-(1H,3H)-dione (4)

To a solution of 8 (100 mg, 0.251 mmol, 1.0 equiv.) and MeI (54 mg, 0.377 mmol, 1.5 equiv.) in DMF (2 mL) was added K₂CO₃ (76 mg, 0.552 mmol, 2.2 equiv.). The mixture was stirred overnight then diluted with aqueous NH₄Cl (20 mL) and extracted with EA (20 mL × 2). The combined organic layer was dried with anhydrous Na₂SO₄, filtered and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (PE to PE/EA = 1 : 2) to give 4 (83 mg, 0.201 mmol) as a white solid, yield: 80%. Single crystal was obtained by slowly evaporating a mixture of 100 mg compound 4 in 5 mL ethyl acetate at ambient temperature and tested by X-ray analysis. ¹H NMR (CDCl₃, 400 MHz): δ (ppm) 7.94 (s, 1H), 7.17–7.09 (m, 1H), 6.99–6.90 (m, 1H), 5.23 (s, 2H), 5.16 (s, 2H), 3.85 (s, 3H), 3.20 (q, J = 7.4 Hz, 2H), 1.33 (t, J = 7.4 Hz, 3H). ¹³C NMR (CDCl₃, 100 MHz): δ (ppm) 169.56, 159.16, 155.09 (ddd, J = 246.7, 9.6, 2.9 Hz), 151.65, 150.51, 151.21–145.64 (m), 144.30, 118.00 (dt, J = 16.3, 4.7 Hz), 116.13 (dd, J = 20.0, 5.4 Hz), 105.74 (dd, J = 27.6, 21.1 Hz), 41.05 (d, J = 4.4 Hz), 39.83, 36.09, 27.24, 13.49. The ¹H NMR and ¹³C NMR data met with the publication.^6b HRMS (ESI+) m/z calcd for C₁₆H₁₆F₃N₆O₂S⁺ [M + H]⁺: 413.1002, found 431.1001.

Preparation of 3-(chloromethyl)-1H-1,2,4-triazole hydrochloride (7·HCl) by tandem one-pot process

2-Chloroacetamide (5.0 g, 53.47 mmol, 1.0 equiv.) was suspended in EA (50 mL) and N,N-dimethyformamide dimethyl acetal (6.7 g, 56.14 mmol, 1.05 equiv.) was added. The resulting mixture was stirred under 50 °C for 1.5 hours., then removed the solvent under reduced pressure to obtained a white solid, and resulting white solid was dissolved in a mixture of 1,4-dioxane (10 mL) and acetic acid (9.6 g, 160.41 mmol, 3.0 equiv.). Hydrazine acetate (5.9 g, 64.16 mmol, 1.2 equiv.) was added and then the resulting mixture was stirred under 50 °C overnight.

The mixture was concentrated under reduced pressure. The residue was diluted with water (100 mL), extracted with EA (100 mL × 3). The combined organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to obtained a yellow oil. The residue was dissolved in EA (10 mL) and then HCl/EA (1 M, 10 mL) was added dropwise to obtain a white suspension, which was filtered and dried to give 3-(chloromethyl)-1H-1,2,4-triazole hydrochloride 7·HCl (5.9 g, 38.50 mmol) as a white solid, yield: 72%. ¹H NMR (DMSO-d₆, 400 MHz) δ (ppm) 8.75 (s, 1H), 7.30 (br s, 2H), 4.80 (s, 2H). ¹³C NMR (DMSO-d₆, 100 MHz) δ (ppm) 157.16, 145.66, 37.05.

Preparation of 6-(ethylthio)-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-(2,4,5-trifluoro-benzyl)-1,3,5-triazine-2,4-(1H,3H)-dione (4) by one-pot process

To a solution of compound 2 (1.0 g, 3.15 mmol, 1.0 equiv.) in DMF (5 mL) was added K₂CO₃ (958 mg, 6.39 mmol, 2.2 equiv.). The mixture was stirred under 40 °C for 0.5 hour. Then 3-(chloromethyl)-1H-1,2,4-triazole 7 (741 mg, 6.30 mmol, 2.0 equiv.) prepared via basification from hydrochloride salt using weak base sodium bicarbonate in ethyl acetate was added and stirred for 5 hours. After no improvement of this reaction was monitored by TLC, MeI (984 mg, 6.93 mmol, 2.2 equiv.) was added. The resulting mixture was stirred overnight.

The reaction mixture was diluted with water (100 mL), extracted with EA (300 mL × 3). The combined organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to afford a residue. The residue was slurried by tert-butyl methyl ether to give 4 (703 mg, 1.70 mmol) as a solid, yield: 54%.

Preparation of 6-(ethylthio)-3-methyl-1-(2,4,5-trifluorobenzyl)-1,3,5-triazine-2,4(1H,3H)-dione (9)

To a solution of material 2 (100 mg, 0.351 mmol, 1.0 equiv.) and MeI (67 mg, 0.47 mmol, 1.5 equiv.) in MeCN (1 mL), K₂CO₃ (87 mg, 0.63 mmol, 2.0 equiv.) was added. The mixture was stirred at room temperature overnight, and then diluted with water (20 mL) and extracted with EA (20 mL × 2). The combined organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE to PE/EA = 5 : 1) to give 9 (94 mg, 0.28 mmol) as a white solid, yield: 90%. ¹H NMR (CDCl₃, 400 MHz): δ (ppm) 7.08–6.93 (m, 2H), 5.14 (s, 2H), 3.39 (d, J = 1.0 Hz, 3H), 3.22 (q, J = 7.4 Hz, 2H), 1.36 (t, J = 7.4 Hz, 3H). ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 169.20, 155.31 (ddd, J = 247.0, 9.5, 2.8 Hz), 152.37, 150.63, 151.61–145.31 (m), 117.99 (dt, J = 16.0, 4.9 Hz), 116.43 (ddd, J = 20.4, 5.0, 1.5 Hz), 106.00 (dd, J = 27.6, 21.0 Hz), 41.51 (d, J = 3.9 Hz), 29.16, 27.29, 13.64. HRMS (ESI+) m/z calcd for C₁₃H₁₃F₃N₃O₂S⁺ [M + H]⁺: 332.0675, found 332.0674.

Preparation of 6-(ethylthio)-3-[(1-methyl-1H-1,2,4-triazol-5-yl)methyl]-1-(2,4,5-trifluorobenzyl)-1,3,5-triazine-2,4-(1H,3H)-dione (10)

To a solution of material 2 (100 mg, 0.35 mmol, 1.0 equiv.) and 5-(chloromethyl)-1H-1,2,4-triazole HCl 3a (80 mg, 0.47 mmol, 1.5 equiv.) in DMF (2 mL) was added K₂CO₃ (131 mg, 0.945 mmol, 3.0 equiv.). The mixture was stirred at 60 °C for 4 hours and then cooled to room temperature. The cooled mixture was diluted with aqueous NH₄Cl (20 mL) and extracted with EA (20 mL × 2). The combined organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE to PE/EA = 1 : 1) to give impurity 10 (104 mg, 0.25 mmol) as a grey viscous oil, yield: 80%. ¹H NMR (CDCl₃, 400 MHz) δ (ppm) 7.74 (s, 1H), 7.19–7.04 (m, 1H), 7.01–6.83 (m, 1H), 5.17 (s, 2H), 5.11 (s, 2H), 3.93 (s, 3H), 3.15 (q, J = 7.4 Hz, 2H), 1.29 (t, J = 7.4 Hz, 3H). ¹³C NMR (CDCl₃, 100 MHz): δ (ppm) 170.32, 155.21 (ddd, J = 246.8, 9.5, 2.8 Hz), 151.43, 150.55, 150.35, 149.93, 151.31–145.51 (m), 117.72 (dt, J = 16.1, 4.8 Hz), 116.50 (dd, J = 19.8, 4.8 Hz), 105.90 (dd, J = 27.6, 21.0 Hz), 41.56 (d, J = 4.0 Hz), 36.94, 35.54, 27.44, 13.52. HRMS (ESI+) m/z calcd for C₁₆H₁₆F₃N₆O₂S⁺ [M + H]⁺: 413.1002, found 413.1001.

Conflicts of interest

There are no conflicts to declare.

Supplementary Material

RA-012-D2RA06841A-s001

RA-012-D2RA06841A-s001.pdf^{(2MB, pdf)}

RA-012-D2RA06841A-s002

RA-012-D2RA06841A-s002.cif^{(1.2MB, cif)}

Acknowledgments

This work was supported by Talent Project of Jiangxi Province (No. jxsq2019101065) and Ganzhou Science and Technology Project (No. 2020-60). The Start-up Fund of Gannan Medical University is gratefully acknowledged.

^†

Electronic supplementary information (ESI) available. CCDC 2212798. For ESI and crystallographic data in CIF or other electronic format see DOI: https://doi.org/10.1039/d2ra06841a

Notes and references

(a) WHO Solidarity Trial Consortium Repurposed antiviral drugs for COVID-19 - interim WHO solidarity trial results. N. Engl. J. Med. 2021;384:497–511. doi: 10.1056/NEJMoa2023184. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) McKimm-Breschkin J. L. Hay A. J. Cao B. Cox R. J. Dunning J. Moen A. C. Olson D. Pizzorno A. Hayden F. G. COVID-19, influenza and RSV: surveillance-informed prevention and treatment – meeting report from an isirv-WHO virtual conference. Antiviral Res. 2022;197:105227. doi: 10.1016/j.antiviral.2021.105227. [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Pan L. Huang P. Xie X. Xu J. Guo D. Jiang Y. Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis. Dig. Liver Dis. 2021;53:153–157. doi: 10.1016/j.dld.2020.09.007. [DOI] [PMC free article] [PubMed] [Google Scholar]; (d) Huang Z. Huang P. Du B. Kong L. Zhang W. Zhang Y. Dong J. Prevalence and clinical outcomes of cardiac injury in patients with covid-19: a systematic review and meta-analysis. Nutr., Metab. Cardiovasc. 2021;31:2–13. doi: 10.1016/j.numecd.2020.09.004. [DOI] [PMC free article] [PubMed] [Google Scholar]; (e) Hu B. Guo H. Zhou P. Shi Z.-L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19:141–154. doi: 10.1038/s41579-020-00459-7. [DOI] [PMC free article] [PubMed] [Google Scholar]; (f) Lin L. Hu K. Cai S. Deng X. Shao X. Liang Y. Wang J. Zhong T. Hu Z. Lei M. Hypoproteinemia is an independent risk factor for the prognosis of severe COVID-19 patients. J. Clin. Biochem. Nutr. 2020;67:126–130. doi: 10.3164/jcbn.20-75. [DOI] [PMC free article] [PubMed] [Google Scholar]; (g) Hu X. Zhu L. Luo Y. Zhao Q. Tan C. Chen X. Zhang H. Hu X. Lu L. Xiao Y. Huang S. He Y. Sim J. X. L. Su S. Wang F. Peng Y. Wang J. Guo Y. Zhong T. Evaluation of the clinical performance of single-, dual-, and triple-target SARS-CoV-2 RT-qPCR methods. Clin. Chim. Acta. 2020;511:143–148. doi: 10.1016/j.cca.2020.10.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
From WHO website: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
(a) Riva L. Yuan S. Yin X. Martin-Sancho L. Matsunaga N. Pache L. Burgstaller-Muehlbacher S. Jesus P. D. D. Teriete P. Hull M. V. Chang M. W. Chan J. F.-W. Cao J. Poon V. K.-M. Herbert K. M. Cheng K. Nguyen T.-T. H. Rubanov A. Pu Y. Nguyen C. Choi A. Rathnasinghe R. Schotsaert M. Miorin L. Dejosez M. Zwaka T. P. Sit K.-Y. Martinez-Sobrido L. Liu W.-C. White K. M. Chapman M. E. Lendy E. K. Glynne R. J. Albrecht R. Ruppin E. Mesecar A. D. Johnson J. R. Benner C. Sun R. Schultz P. G. Su A. I. García-Sastre A. Chatterjee A. K. Yuen K.-Y. Chanda S. K. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586:113–119. doi: 10.1038/s41586-020-2577-1. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Halford B. The path to paxlovid. ACS Cent. Sci. 2022;8:405–407. doi: 10.1021/acscentsci.2c00369. [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Owen D. R. Allerton C. M. N. Anderson A. S. Aschenbrenner L. Avery M. Berritt S. Boras B. Cardin R. D. Carlo A. Coffman K. J. Dantonio A. Di L. Eng H. Ferre R. Gajiwala K. S. Gibson S. A. Greasley S. E. Hurst B. L. Kadar E. P. Kalgutkar A. S. Lee J. C. Lee J. Liu W. Mason S. W. Noell S. Novak J. J. Obach R. S. Ogilvie K. Patel N. C. Pettersson M. Rai D. K. Reese M. R. Sammons M. F. Sathish J. G. Singh R. S. P. Steppan C. M. Stewart A. E. Tuttle J. B. Updyke L. Verhoest P. R. Wei L. Yang Q. Zhu Y. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586–1593. doi: 10.1126/science.abl4784. [DOI] [PubMed] [Google Scholar]
Yang K. S. Leeuwon S. Z. Xu S. Liu W. R. Evolutionary and structural insights about potential SARS-CoV-2 evasion of nirmatrelvir. J. Med. Chem. 2022;65:8686–8698. doi: 10.1021/acs.jmedchem.2c00404. [DOI] [PMC free article] [PubMed] [Google Scholar]
Tan H. Hu Y. Jadhav P. Tan B. Wang J. Progress and challenges in targeting the SARS-CoV-2 papain-like protease. J. Med. Chem. 2022;65:7561–7580. doi: 10.1021/acs.jmedchem.2c00303. [DOI] [PMC free article] [PubMed] [Google Scholar]
(a) Tyndall J. D. A. S-217622, a 3CL protease inhibitor and clinical candidate for SARS-CoV-2. J. Med. Chem. 2022;65:6496–6498. doi: 10.1021/acs.jmedchem.2c00624. [DOI] [PubMed] [Google Scholar]; (b) Unoh Y. Uehara S. Nakahara K. Nobori H. Yamatsu Y. Yamamoto S. Maruyama Y. Taoda Y. Kasamatsu K. Suto T. Kouki K. Nakahashi A. Kawashima S. Sanaki T. Toba S. Uemura K. Mizutare T. Ando S. Sasaki M. Orba Y. Sawa H. Sato A. Sato T. Kato T. Tachibana Y. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 2022;65:6499–6512. doi: 10.1021/acs.jmedchem.2c00117. [DOI] [PMC free article] [PubMed] [Google Scholar]
Sasaki M. Tabata K. Kishimoto M. Itakura Y. Kobayashi H. Ariizumi T. Uemura K. Toba S. Kusakabe S. Maruyama Y. Iida S. Nakajima N. Suzuki T. Yoshida S. Nobori H. Sanaki T. Kato T. Shishido T. Hall W. W. Orba Y. Sato A. Sawa H. Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases the viral load and accelerates recovery from clinical aspects of COVID-19. bioRxiv. 2022 doi: 10.1101/2022.02.14.480338. [DOI] [Google Scholar]
From Shionogi's Website: https://www.shionogi.com/global/en/news/2022/09/20220928.html
(a) Owen S. N., Swain C. J. and Williams B. J., Substituted morpholine derivative and its use as a therapeutic agent, 1999 [Google Scholar]; (b) Bechstein U. Rumler A. Liebscher J. Efficient syntheses of ω-chloro-, ω-imido- and ω-aminoalkyl-1,2,4-triazoles from N-acyl-formamidinium salts or N-acylformamides and hydrazines. Arch. Pharm. 1992;325:519–529. doi: 10.1002/ardp.19923250813. [DOI] [Google Scholar]; (c) Xi M. Feng C. Du K. Lv W. Du C. Shen R. Sun H. Design, synthesis, biological evaluation and molecular modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4-yl)methyl)benzo[d][1,3] dioxole-5-carboxamides as selective butyrylcholinesterase inhibitors. Bioorg. Med. Chem. Lett. 2022;61:128602. doi: 10.1016/j.bmcl.2022.128602. [DOI] [PubMed] [Google Scholar]
Gao F., Zeng S., Jiang J. and Zhang X., Method for preparing (1-methyl-1H-[1,2,4]triazole-3-yl)-methyl alcohol, Invention Pat., CN107879992A, 2017
Harit T. Bellaouchi R. Rokni Y. Riahi A. Malek F. Asehraou A. Synthesis, characterization, antimicrobial activity and docking studies of new triazolic tripodal ligands. Chem. Biodiversity. 2017;14:e1700351. doi: 10.1002/cbdv.201700351. [DOI] [PubMed] [Google Scholar]
Xu Y. McLaughlin M. Bolton E. N. Reamer R. A. Practical synthesis of functionalized 1,5-disubstituted 1,2,4-triazole derivatives. J. Org. Chem. 2010;75:8666–8669. doi: 10.1021/jo1017603. [DOI] [PubMed] [Google Scholar]
Hoashi Y. Takai T. Kosugi Y. Nakashima M. Nakayama M. Hirai K. Uchikawa O. Koike T. Discovery of a potent and orally bioavailable melatonin receptor agonist. J. Med. Chem. 2021;64:3059–3074. doi: 10.1021/acs.jmedchem.0c01836. [DOI] [PubMed] [Google Scholar]
Shen S. Hadley M. Ustinova K. Pavlicek J. Knox T. Noonepalle S. Tavares M. T. Zimprich C. A. Zhang G. Robers M. B. Bařinka C. Kozikowski A. P. Villagra A. Discovery of a new isoxazole-3-hydroxamate-based histone deacetylase 6 inhibitor ss-208 with antitumor activity in syngeneic melanoma mouse models. J. Med. Chem. 2019;62:8557–8577. doi: 10.1021/acs.jmedchem.9b00946. [DOI] [PubMed] [Google Scholar]
Jones R. G. Ainsworth C. 1,2,4-Triazole-3-alanine. J. Am. Chem. Soc. 1955;77:1538–1540. doi: 10.1021/ja01611a040. [DOI] [Google Scholar]
Tasaka A. Teranishi K. Matsushita Y. Tamura N. Hayashi R. Okonogi K. Itoh K. Optically active antifungal azoles. III. Synthesis and antifungal activity of sulfide and sulfonamide derivatives of (2R,3R)-2-(2,4-difluorophenyl)-3- mercapto-1-(1H-1,2,4-triazol-1-yl)-2-butanol. Chem. Pharm. Bull. 1994;42:85–94. doi: 10.1248/cpb.42.85. [DOI] [PubMed] [Google Scholar]
Wildonger K. J. Ratcliffe R. W. Heteroaryliumthio substituted carbapenem derivatives: Synthesis and in vitro activity of 1β-methyl-2-(dihydropyrrolotriazoliumthio)carbapenems. J. Antibiot. 1993;46:1866–1882. doi: 10.7164/antibiotics.46.1866. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

RA-012-D2RA06841A-s001

RA-012-D2RA06841A-s001.pdf^{(2MB, pdf)}

RA-012-D2RA06841A-s002

RA-012-D2RA06841A-s002.cif^{(1.2MB, cif)}

[cit2] From WHO website: https://www.who.int/emergencies/diseases/novel-coronavirus-2019

[cit3] (a) Riva L. Yuan S. Yin X. Martin-Sancho L. Matsunaga N. Pache L. Burgstaller-Muehlbacher S. Jesus P. D. D. Teriete P. Hull M. V. Chang M. W. Chan J. F.-W. Cao J. Poon V. K.-M. Herbert K. M. Cheng K. Nguyen T.-T. H. Rubanov A. Pu Y. Nguyen C. Choi A. Rathnasinghe R. Schotsaert M. Miorin L. Dejosez M. Zwaka T. P. Sit K.-Y. Martinez-Sobrido L. Liu W.-C. White K. M. Chapman M. E. Lendy E. K. Glynne R. J. Albrecht R. Ruppin E. Mesecar A. D. Johnson J. R. Benner C. Sun R. Schultz P. G. Su A. I. García-Sastre A. Chatterjee A. K. Yuen K.-Y. Chanda S. K. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586:113–119. doi: 10.1038/s41586-020-2577-1. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Halford B. The path to paxlovid. ACS Cent. Sci. 2022;8:405–407. doi: 10.1021/acscentsci.2c00369. [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Owen D. R. Allerton C. M. N. Anderson A. S. Aschenbrenner L. Avery M. Berritt S. Boras B. Cardin R. D. Carlo A. Coffman K. J. Dantonio A. Di L. Eng H. Ferre R. Gajiwala K. S. Gibson S. A. Greasley S. E. Hurst B. L. Kadar E. P. Kalgutkar A. S. Lee J. C. Lee J. Liu W. Mason S. W. Noell S. Novak J. J. Obach R. S. Ogilvie K. Patel N. C. Pettersson M. Rai D. K. Reese M. R. Sammons M. F. Sathish J. G. Singh R. S. P. Steppan C. M. Stewart A. E. Tuttle J. B. Updyke L. Verhoest P. R. Wei L. Yang Q. Zhu Y. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586–1593. doi: 10.1126/science.abl4784. [DOI] [PubMed] [Google Scholar]

[cit4] Yang K. S. Leeuwon S. Z. Xu S. Liu W. R. Evolutionary and structural insights about potential SARS-CoV-2 evasion of nirmatrelvir. J. Med. Chem. 2022;65:8686–8698. doi: 10.1021/acs.jmedchem.2c00404. [DOI] [PMC free article] [PubMed] [Google Scholar]

[cit5] Tan H. Hu Y. Jadhav P. Tan B. Wang J. Progress and challenges in targeting the SARS-CoV-2 papain-like protease. J. Med. Chem. 2022;65:7561–7580. doi: 10.1021/acs.jmedchem.2c00303. [DOI] [PMC free article] [PubMed] [Google Scholar]

[cit6] (a) Tyndall J. D. A. S-217622, a 3CL protease inhibitor and clinical candidate for SARS-CoV-2. J. Med. Chem. 2022;65:6496–6498. doi: 10.1021/acs.jmedchem.2c00624. [DOI] [PubMed] [Google Scholar]; (b) Unoh Y. Uehara S. Nakahara K. Nobori H. Yamatsu Y. Yamamoto S. Maruyama Y. Taoda Y. Kasamatsu K. Suto T. Kouki K. Nakahashi A. Kawashima S. Sanaki T. Toba S. Uemura K. Mizutare T. Ando S. Sasaki M. Orba Y. Sawa H. Sato A. Sato T. Kato T. Tachibana Y. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 2022;65:6499–6512. doi: 10.1021/acs.jmedchem.2c00117. [DOI] [PMC free article] [PubMed] [Google Scholar]

[cit7] Sasaki M. Tabata K. Kishimoto M. Itakura Y. Kobayashi H. Ariizumi T. Uemura K. Toba S. Kusakabe S. Maruyama Y. Iida S. Nakajima N. Suzuki T. Yoshida S. Nobori H. Sanaki T. Kato T. Shishido T. Hall W. W. Orba Y. Sato A. Sawa H. Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases the viral load and accelerates recovery from clinical aspects of COVID-19. bioRxiv. 2022 doi: 10.1101/2022.02.14.480338. [DOI] [Google Scholar]

[cit8] From Shionogi's Website: https://www.shionogi.com/global/en/news/2022/09/20220928.html

[cit9] (a) Owen S. N., Swain C. J. and Williams B. J., Substituted morpholine derivative and its use as a therapeutic agent, 1999 [Google Scholar]; (b) Bechstein U. Rumler A. Liebscher J. Efficient syntheses of ω-chloro-, ω-imido- and ω-aminoalkyl-1,2,4-triazoles from N-acyl-formamidinium salts or N-acylformamides and hydrazines. Arch. Pharm. 1992;325:519–529. doi: 10.1002/ardp.19923250813. [DOI] [Google Scholar]; (c) Xi M. Feng C. Du K. Lv W. Du C. Shen R. Sun H. Design, synthesis, biological evaluation and molecular modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4-yl)methyl)benzo[d][1,3] dioxole-5-carboxamides as selective butyrylcholinesterase inhibitors. Bioorg. Med. Chem. Lett. 2022;61:128602. doi: 10.1016/j.bmcl.2022.128602. [DOI] [PubMed] [Google Scholar]

[cit10] Gao F., Zeng S., Jiang J. and Zhang X., Method for preparing (1-methyl-1H-[1,2,4]triazole-3-yl)-methyl alcohol, Invention Pat., CN107879992A, 2017

[cit11] Harit T. Bellaouchi R. Rokni Y. Riahi A. Malek F. Asehraou A. Synthesis, characterization, antimicrobial activity and docking studies of new triazolic tripodal ligands. Chem. Biodiversity. 2017;14:e1700351. doi: 10.1002/cbdv.201700351. [DOI] [PubMed] [Google Scholar]

[cit12] Xu Y. McLaughlin M. Bolton E. N. Reamer R. A. Practical synthesis of functionalized 1,5-disubstituted 1,2,4-triazole derivatives. J. Org. Chem. 2010;75:8666–8669. doi: 10.1021/jo1017603. [DOI] [PubMed] [Google Scholar]

[cit13] Hoashi Y. Takai T. Kosugi Y. Nakashima M. Nakayama M. Hirai K. Uchikawa O. Koike T. Discovery of a potent and orally bioavailable melatonin receptor agonist. J. Med. Chem. 2021;64:3059–3074. doi: 10.1021/acs.jmedchem.0c01836. [DOI] [PubMed] [Google Scholar]

[cit14] Shen S. Hadley M. Ustinova K. Pavlicek J. Knox T. Noonepalle S. Tavares M. T. Zimprich C. A. Zhang G. Robers M. B. Bařinka C. Kozikowski A. P. Villagra A. Discovery of a new isoxazole-3-hydroxamate-based histone deacetylase 6 inhibitor ss-208 with antitumor activity in syngeneic melanoma mouse models. J. Med. Chem. 2019;62:8557–8577. doi: 10.1021/acs.jmedchem.9b00946. [DOI] [PubMed] [Google Scholar]

[cit15] Jones R. G. Ainsworth C. 1,2,4-Triazole-3-alanine. J. Am. Chem. Soc. 1955;77:1538–1540. doi: 10.1021/ja01611a040. [DOI] [Google Scholar]

[cit16] Tasaka A. Teranishi K. Matsushita Y. Tamura N. Hayashi R. Okonogi K. Itoh K. Optically active antifungal azoles. III. Synthesis and antifungal activity of sulfide and sulfonamide derivatives of (2R,3R)-2-(2,4-difluorophenyl)-3- mercapto-1-(1H-1,2,4-triazol-1-yl)-2-butanol. Chem. Pharm. Bull. 1994;42:85–94. doi: 10.1248/cpb.42.85. [DOI] [PubMed] [Google Scholar]

[cit17] Wildonger K. J. Ratcliffe R. W. Heteroaryliumthio substituted carbapenem derivatives: Synthesis and in vitro activity of 1β-methyl-2-(dihydropyrrolotriazoliumthio)carbapenems. J. Antibiot. 1993;46:1866–1882. doi: 10.7164/antibiotics.46.1866. [DOI] [PubMed] [Google Scholar]

PERMALINK

Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19†

Wei Hu

Xiang Zhang

Yuanchang Liu

Teng Liu

Jiale Wen

Xiaopeng Peng

Xin Xie

Weiming Chen

Abstract

Introduction

Scheme 1. Shionogi's synthetic strategy for ensitrelvir. Reagents and conditions: (a) K2CO3, DMF, 60 °C, 3.5 h, 45%; and (b) 6-chloro-2-methyl-2H-indazol-5-amine, LiHMDS, THF, 0 °C to r.t., 25%.

Scheme 2. The three existing synthetic strategies for preparing chloromethyl triazole 3.

Results and discussion

Investigation into the preparation of 1,2,4-triazole derivatives

Investigation of N-alkylation and N1-methylation to triazone-triazole 4

Scheme 4. Investigation of N-alkylation and N1-methylation to prepare triazone-triazole. Reagents and conditions: (a) K2CO3, DMF, 60 °C, 3.5 h, 25%; and (b) MeI, K2CO3, DMF, r.t., overnight, 80%.

Preliminary optimization

Trials of N-alkylation of 7 and 2a.

Scheme 6. Generation and preparation of the two main impurities.